Dr. Munshi on the Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Kraft Family Chair, senior physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
Patients with relapsed/refractory multiple myeloma have limited treatment options that often do not lead to significant responses, says Munshi.
CAR T-cell therapy has elicited high response rates in this setting for patients who are heavily pretreated, explains Munshi.
Data from the phase 2 KarMMA trial revealed that the CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121) induced a 73.4% overall response rate in patients with relapsed/refractory multiple myeloma. Additionally, topline results from the trial showed a complete response rate of 31.3%.
Although other potential targets are being evaluated in the space, BCMA is a validated target worthy of continued investigation, says Munshi. As such, CAR T-cell therapy is poised to have significant impact on the treatment of patients with multiple myeloma.
Transplant Eligibility Versus CAR-T Eligibility
January 16th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.
